miRNA |
Drug Name |
CID |
NSC |
FDA |
Effect/Pattern |
Detection Method |
Level |
Phenotype |
Condition |
hsa-mir-708 |
Tamoxifen |
2733525 |
NSC180973 |
approved |
sensitive |
|
Low |
Breast Cancer |
cell line (MCF-7, T47D) |
hsa-mir-708 |
Dabrafenib |
44462760 |
NSC764134 |
approved |
sensitive |
|
|
|
cell line (A375) |
hsa-mir-708 |
Paclitaxel |
36314 |
NSC125973 |
approved |
resistant |
|
|
|
cell line (W1) |
hsa-mir-708 |
Cisplatin |
5460033 |
NSC119875 |
approved |
resistant |
|
|
|
cell line (W1) |
hsa-mir-708 |
Methotrexate |
126941 |
NSC740 |
approved |
sensitive |
|
|
|
cell line (W1) |
hsa-mir-708 |
Topotecan |
60699 |
NSC609699 |
approved |
resistant |
|
|
|
cell line (W1) |
hsa-mir-708 |
Vincristine |
5978 |
|
approved |
sensitive |
|
|
|
cell line (W1) |
hsa-mir-708 |
Tamoxifen |
2733525 |
NSC180973 |
approved |
sensitive |
|
|
|
cell line (MCF7) |
hsa-mir-708 |
Ceritinib |
57379345 |
NSC776422 |
approved |
sensitive |
|
|
|
cell line (H3122) |
hsa-miR-708-5p |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
High |
Germ Cell Tumor |
cell line (NTERA-2) |
hsa-miR-708-5p |
Modified Allic Bfm 2002 Protocol |
|
|
|
resistant |
|
High |
Childhood Acute Lymphoblastic Leukemia |
tissue |
hsa-miR-708-5p |
Etoposide |
36462 |
NSC141540 |
approved |
sensitive |
|
Low |
Ewing Sarcoma |
cell line (A673) |
hsa-miR-708-5p |
Doxorubicin |
31703 |
NSC123127 |
approved |
sensitive |
|
Low |
Ewing Sarcoma |
cell line (A673) |
hsa-miR-708-5p |
Gemcitabine |
60750 |
NSC613327 |
approved |
resistant |
|
High |
Cholangiocarcinoma |
cell line (HuCCT1, HuH28) |
hsa-miR-708-5p |
Chemotherapy |
|
|
|
sensitive |
|
High |
Epithelial Ovarian Cancer |
tissue |
hsa-miR-708-5p |
Doxorubicin |
31703 |
NSC123127 |
approved |
sensitive |
|
High |
Hepatocellular Carcinoma |
tissue and cell line (HepG2) |
hsa-miR-708-5p |
Doxorubicin |
31703 |
NSC123127 |
approved |
sensitive |
|
Low |
Renal Cell Cancer |
cell line (Caki) |
hsa-miR-708-5p |
Thapsigargin |
446378 |
|
|
sensitive |
|
Low |
Renal Cell Cancer |
cell line (Caki) |
hsa-miR-708-5p |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
Low |
Cervical Cancer |
tissue |
hsa-miR-708-5p |
Tamoxifen |
2733525 |
NSC180973 |
approved |
sensitive |
|
High |
Breast Cancer |
cell line (TAMR4) |
hsa-miR-708-5p |
Aromatase Inhibitor |
|
|
|
sensitive |
|
Low |
Breast Cancer |
cell line (MCF-7) |
hsa-miR-708-5p |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
High |
Gallbladder Cancer |
cell line (GBC-SD, NOZ) |
hsa-miR-708-5p |
Dabrafenib |
44462760 |
NSC764134 |
approved |
resistant |
|
High |
Melanoma |
cell line (A375, IGR37, 501Mel) |
hsa-miR-708-5p |
Dabrafenib |
44462760 |
NSC764134 |
approved |
sensitive |
|
High |
Melanoma |
cell line (A375, IGR37, 501Mel) |
hsa-miR-708-5p |
Vemurafenib |
42611257 |
NSC761431 |
approved |
resistant |
|
High |
Melanoma |
cell line (A375, IGR37, 501Mel) |
hsa-miR-708-5p |
Vemurafenib |
42611257 |
NSC761431 |
approved |
sensitive |
|
High |
Melanoma |
cell line (A375, IGR37, 501Mel) |
hsa-miR-708-5p |
Paclitaxel |
36314 |
NSC125973 |
approved |
sensitive |
|
High |
Non-Small Cell Lung Cancer |
cell line (A549) |
hsa-miR-708-5p |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
Low |
Ovarian Cancer |
cell line (SKOV3, A2780) |
hsa-miR-708-5p |
Cisplatin |
5460033 |
NSC119875 |
approved |
resistant |
|
Low |
Urothelial Bladder Cancer |
cell line (T24) |
hsa-miR-708-5p |
Gemcitabine |
60750 |
NSC613327 |
approved |
resistant |
|
Low |
Urothelial Bladder Cancer |
cell line (T24) |
hsa-miR-708-5p |
Vemurafenib |
42611257 |
NSC761431 |
approved |
sensitive |
|
High |
Melanoma |
cell line (WM266) (200nM) |
hsa-miR-708-5p |
Vemurafenib |
42611257 |
NSC761431 |
approved |
sensitive |
|
High |
Melanoma |
cell line (WM266) (2uM) |
hsa-miR-708-5p |
Trametinib |
11707110 |
NSC758246 |
approved |
sensitive |
|
High |
Melanoma |
cell line (WM266) (2uM) |
hsa-miR-708-5p |
Trametinib |
11707110 |
NSC758246 |
approved |
sensitive |
|
High |
Melanoma |
cell line (WM266) (200nM) |
hsa-miR-708-5p |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
High |
Non-Small Cell Lung Cancer |
cell line (A549, HCC827) |
hsa-miR-708-5p |
Gefitinib |
123631 |
NSC715055 |
approved |
sensitive |
|
High |
Non-Small Cell Lung Cancer |
cell line (A549, HCC827) |
hsa-miR-708-5p |
Trail + R428 |
|
|
|
sensitive |
|
Low |
Renal Cell Cancer |
cell line (Caki, ACHN, A498, A549, HepG2) |
hsa-miR-708-5p |
Platinum |
23939 |
|
|
resistant |
|
High |
High-Grade Serous Ovarian Cancer |
tissue |
hsa-miR-708-5p |
Cyclophosphamide |
2907 |
NSC26271 |
approved |
sensitive |
|
High |
Diffuse Large B-Cell Lymphoma |
cell line (DB, NU-DHL-1, NU-DUL-1, MC-116, SU-DHL-4, SU-DHL-5, FARAGE, HBL-1, OCI-Ly3, OCI-Ly7, OCI-Ly8, OCI-Ly19, RIVA, SU-DHL-8, U2932) |
hsa-miR-708-5p |
Rituximab |
|
|
|
resistant |
|
High |
Diffuse Large B-Cell Lymphoma |
cell line (DB, NU-DHL-1, NU-DUL-1, MC-116, SU-DHL-4, SU-DHL-5, FARAGE, HBL-1, OCI-Ly3, OCI-Ly7, OCI-Ly8, OCI-Ly19, RIVA, SU-DHL-8, U2932) |
hsa-miR-708-5p |
Doxorubicin |
31703 |
NSC123127 |
approved |
sensitive |
|
High |
Diffuse Large B-Cell Lymphoma |
cell line (DB, NU-DHL-1, NU-DUL-1, MC-116, SU-DHL-4, SU-DHL-5, FARAGE, HBL-1, OCI-Ly3, OCI-Ly7, OCI-Ly8, OCI-Ly19, RIVA, SU-DHL-8, U2932) |
hsa-miR-708-5p |
Vincristine |
5978 |
|
approved |
sensitive |
|
High |
Diffuse Large B-Cell Lymphoma |
cell line (DB, NU-DHL-1, NU-DUL-1, MC-116, SU-DHL-4, SU-DHL-5, FARAGE, HBL-1, OCI-Ly3, OCI-Ly7, OCI-Ly8, OCI-Ly19, RIVA, SU-DHL-8, U2932) |
hsa-miR-708-5p |
Cisplatin |
5460033 |
NSC119875 |
approved |
resistant |
|
High |
Ovarian Cancer |
cell line (W1) |
hsa-miR-708-5p |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
High |
Non-Small Cell Lung Cancer |
cell line (A549) |
hsa-miR-708-5p |
Temozolomide |
5394 |
NSC362856 |
approved |
sensitive |
|
|
|
cell line (U251) |
hsa-miR-708-5p |
Gefitinib |
123631 |
NSC715055 |
approved |
resistant |
|
|
|
cell line (PC9) |
hsa-miR-708-5p |
Gefitinib |
123631 |
NSC715055 |
approved |
resistant |
|
|
|
cell line (HCC827) |
hsa-miR-708-5p |
Vemurafenib |
42611257 |
NSC761431 |
approved |
sensitive |
|
|
|
cell line (451Lu) |
hsa-miR-708-5p |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
|
|
cell line (A549) |
hsa-miR-708-5p |
Gefitinib |
123631 |
NSC715055 |
approved |
sensitive |
|
|
|
cell line (HCC827) |
hsa-miR-708-5p |
Paclitaxel |
36314 |
NSC125973 |
approved |
sensitive |
|
|
|
cell line (SKVO3ip1) |
hsa-miR-708-5p |
Paclitaxel |
36314 |
NSC125973 |
approved |
resistant |
|
|
|
cell line (HeyA8) |
hsa-miR-708-5p |
Paclitaxel |
36314 |
NSC125973 |
approved |
sensitive |
|
|
|
cell line (BAS) |
hsa-miR-708-5p |
Doxorubicin |
31703 |
NSC123127 |
approved |
sensitive |
|
|
|
cell line (BAS) |
hsa-miR-708-5p |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
|
|
cell line (A549) |
hsa-miR-708-5p |
Tamoxifen+Fulvestrant |
|
|
|
resistant |
|
|
|
cell line (LCC9) |
hsa-miR-708-5p |
Ethanol+Tamoxifen |
|
|
|
sensitive |
|
|
|
cell line (LY2) |
hsa-miR-708-5p |
Methotrexate |
126941 |
NSC740 |
approved |
resistant |
|
|
|
cell line (HT29) |
hsa-miR-708-5p |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
|
|
cell line (RPMI2650) |
hsa-miR-708-5p |
Gemcitabine |
60750 |
NSC613327 |
approved |
resistant |
|
|
|
cell line (HuH28) |
hsa-miR-708-5p |
Tamoxifen |
2733525 |
NSC180973 |
approved |
sensitive |
|
|
|
cell line (TamR4) |
hsa-miR-708-5p |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
|
|
cell line (IGROV-1) |
hsa-miR-708-5p |
Cisplatin |
5460033 |
NSC119875 |
approved |
sensitive |
|
|
|
cell line (A549) |
hsa-miR-708-5p |
Gemcitabine |
60750 |
NSC613327 |
approved |
resistant |
|
|
|
cell line (Panc1-GR4) |
hsa-miR-708-5p |
Ceritinib |
57379345 |
NSC776422 |
approved |
sensitive |
|
|
|
cell line (H3122) |
hsa-miR-708-5p |
Paclitaxel/Docetaxel/Vinorelbine/Doxorubicin/Etoposide |
|
|
|
resistant |
|
|
|
cell line (Bads-200) |
hsa-miR-708-5p |
Paclitaxel/Docetaxel/Vinorelbine/Doxorubicin/Etoposide/Methotrexate/Gemcitabine |
|
|
|
resistant |
|
|
|
cell line (Bats-72) |
|